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Available online 05 July 2016123I-ioﬂupane single photon emission computed tomography (SPECT) is a sensitive andwell established imaging
tool in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS), yet a discrimination between PD
andAPS has been considered inconsistent at least based on visual inspection or simple region of interest analyses.
We here reappraise this issue by applying advanced image analysis techniques to separate PD from the various
APS.
This study included 392 consecutive patients with degenerative parkinsonism undergoing 123I-ioﬂupane SPECT
at our institution over the last decade: 306 PD, 24 multiple system atrophy (MSA), 32 progressive supranuclear
palsy (PSP) and 30 corticobasal degeneration (CBD) patients. Data analysis included voxel-wise univariate statis-
tical parametric mapping and multivariate pattern recognition using linear discriminant classiﬁers.
MSA and PSP showed less ioﬂupane uptake in the head of caudate nucleus relative to PD and CBD, yet there was
no difference between MSA and PSP. CBD had higher uptake in both putamen relative to PD, MSA and PSP. Clas-
siﬁcation was signiﬁcant for PD versus APS (AUC 0.69, p b 0.05) and between APS subtypes (MSA vs CBD AUC
0.80, p b 0.05; MSA vs PSP AUC 0.69 p b 0.05; CBD vs PSP AUC 0.69 p b 0.05).
Both striatal and extra-striatal regions contain classiﬁcation information, yet the combination of both regions
does not signiﬁcantly improve classiﬁcation accuracy.
PD, MSA, PSP and CBD have distinct patterns of dopaminergic depletion on 123I-ioﬂupane SPECT. The high spec-
iﬁcity of 84–90% for PD versus APS indicates that the classiﬁer is particularly useful for conﬁrming APS cases.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Parkinson's disease
Atypical parkinsonism
Single photon emission computed tomography
(SPECT)
Multi vector pattern analysis (MVPA)1. Introduction
With a prevalence ranging from 1 to 2% in the population above
65 years of age, Parkinson's disease (PD) is the most common neurode-
generative movement disorder. Other less common forms of degenera-
tive parkinsonism, collectively referred to as atypical parkinsonian
syndromes (APS), include multiple system atrophy (MSA), progressive
supranuclear palsy (PSP) and corticobasal degeneration (CBD).CBD, corticobasal degeneration;
tern Analysis; PD, Parkinson's
ion of interest; SPECT, single
ctor machines.
Radiologique de Carouge CDRC,
en access article under the CC BY-NCWhereas a clinical diagnosis of PD can be established with accuracy su-
perior to 90% when assessed by an experienced movement disorders
specialist, this is not the case for APS where diagnostic accuracy varies
between 50 and 80% at the very best. This diagnosis issue is even
more problematic at early stages when all suggestive features are not
present (Hughes et al., 2002). Dissecting apart degenerative parkinson-
isms is however important with respect to both treatment and progno-
sis. While PD patients typically respond well to dopamine replacement
therapy, have a slower progression and a good prognosis at 10 years,
APS typically respond less or not at all to dopaminergic medications,
have a more rapid disease course and a much worse outcome.
Neuroimaging may complement clinical assessment and 123I-
ioﬂupane single photon emission computed tomography (SPECT) has
recently become a reliable clinical imaging tool to assess the integrity
of the nigrostriatal dopaminergic system (Brücke et al., 1997;-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and clinical characteristics.
PD APS Stat.
MSA PSP CBD
Sex (m/f) 164/142 13/11 21/11 16/14 n.s
Age (year) 69.4 ± 11 64.6 ± 10.0 72.9 ± 8.3 73.9 ± 7.1 ⁎⁎
Disease duration (year) 2.4 ± 0.9 3.2 ± 3.1 1.9 ± 1.2 2.4 ± 1.8 ⁎
This table summarized the essential demographic data of the patient groups.
⁎ p b 0.05.
⁎⁎ p b 0.01.
235S. Badoud et al. / NeuroImage: Clinical 12 (2016) 234–240Cummings et al., 2011). This technique has a high sensitivity to detect
PD versus controls even at an early stage, yet the pattern of alterations
of the dopaminergic system is quite similar between PD and APS
(Brücke et al., 1997; Kägi et al., 2010; Sixel-Döring et al., 2011). Conse-
quently, simple visual or region of interest (ROI)-based analyses, as rou-
tinely performed in most centers, do not seem to allow a robust
distinction between PD and APS (Brooks, 2012; Kägi et al., 2010;
Klaffke et al., 2006; Marek et al., 2000; Pirker et al., 2000a), so that
123I-ioﬂupane SPECT is currently not recommended for the differential
diagnosis of degenerative parkinsonism.
The current investigation intends to reappraise this diagnostic issue
based on the assumption that systematic but subtle differences in 123I-
ioﬂupane SPECT between PD and APS can be consistently detected
using advanced data analysis techniques. Previous investigations apply-
ing support vector machines (SVM), a type of Multi Voxel Pattern Anal-
ysis (MVPA), successfully discriminated PD from APS patients based on
MRI diffusion tensor imaging (DTI) (Haller et al., 2012),MRI susceptibil-
ity weighted imaging (SWI) (Haller et al., 2013) and gait analysis (Tahir
andManap, 2012). This SVM classiﬁcation techniquewas also applied to
123I-ioﬂupane SPECT data to discriminate 95 PD versus 94 controls
(Segovia et al., 2012) and to discriminate 56 PD versus 34 non-PD (es-
sential tremor and drug-induced parkinsonism) patients (Palumbo et
al., 2014). A comparison between PD and APSwas not performed as yet.
The present study includes a large cohort of 392 consecutive patients
with a clinical diagnosis of PD, MSA, PSP and CBD scanned on the same
tomograph, in the same center over a period of 10 years. We performed
univariate statistical parametric mapping and multivariate pattern rec-
ognition classiﬁcation analyses to test the hypothesis that PD and APS
have distinct patterns of dopaminergic depletion on 123I-ioﬂupane
SPECT, which may enable a clinically useful discrimination between
groups.
2. Materials and methods
2.1. Participants
The present retrospective study was approved by the local ethics
committee and includes 970 consecutive patients undergoing 123I-
ioﬂupane SPECT scanning in our institution between October 2003
and September 2013. 392 participants met our inclusion criteria: 1)
123I-ioﬂupane SPECT of high quality, 2) extensive neurological assess-
ment and 3) clinical follow-up over many years for most patients, and
4) no signiﬁcant morphological ﬁndings on structural images based on
magnetic resonance imaging (MRI) unrelated to neurodegeneration.
UK Parkinson's disease society brain bank criteria were used for the di-
agnosis of PD. They include the presence of bradykinesia associated
with one of the following criteria: 4–6Hz rest tremor, rigidity or postur-
al instability. Other supportive criteria considered as essential were a
very good and sustained response to levodopa, development of typical
levodopa-induced dyskinesia, a unilateral onset and a slowly progres-
sive course. This assessment was achieved by an experienced move-
ment disorders specialist. Regarding APS diagnoses, we strictly applied
well-established, validated and recent criteria, including the second
consensus statement for the diagnosis of MSA (Gilman et al., 2008),
the National Institute of Neurological Disorders Society (NINDS) clinical
research criteria for PSP (Litvan et al., 1996) and the criteria for the diag-
nosis of CBD proposed by (Armstrong et al., 2013). Cases who did not
fulﬁll those sets of criteriawere excluded. Thanks to the usually long fol-
low-up period for most cases, 12 out of the 392 included patients (3.1%)
had their diagnosis changed over time (PD for MSA in 4, PD for PSP in 2,
MSA for PD in 2, CBD for PD in 2, PSP for CBD in 1 and CBD for PSP in 1).
In these cases, only the most recent diagnosis was considered for
classiﬁcation.
It is important to note that the 123I-ioﬂupane SPECT was not used to
conﬁrm a speciﬁc diagnosis but to exclude non-degenerative parkin-
sonisms. Similarly, MRI was performed to exclude secondary forms ofparkinsonism, such as vascular parkinsonismor normal pressure hydro-
cephalus, but not as a supportive diagnostic biomarker for PD or APS.
The ﬁnal sample included 306 PD patients (54% male, age 69.4 ±
11 years, disease duration 2.4 ± 0.9 years at the time of scan) 24 MSA
(54% males, age 64.6 ± 10.0 years, disease duration 3.2 ± 3.1 years),
32 PSP (66% males, age 72.9 ± 8.3 years, disease duration 1.9 ±
1.2 years) and 30CBD(53%males, age 73.9±7.1 years, disease duration
2.4± 1.8 years). 301 of the 306 PD patients were reported in a previous
investigation, which describes the spatio-temporal pattern of dopami-
nergic depletion in PD (Badoud et al., 2016), and re-used as a reference
group in the current investigation. In contrast, the current investigation
aims to classify APS, whichwere not included in the previous investiga-
tion. According to the ANOVA multiple comparison test, there was no
signiﬁcant difference between groups concerning the sex ratio. The
ANOVA test revealed signiﬁcant differences between groups in terms
of age (p = 0.019) and disease duration (p = 0.007) (see Table 1).2.2. SPECT image acquisition
Sodium perchlorate or Lugol solution were preventively adminis-
tered to the patients in order to block thyroid uptake. Patients were
scanned on a triple-head gamma-camera (Toshiba Medical Systems,
Tokyo, Japan) with fan-beam, low-energy, high-resolution collimators,
4 h after intravenous injection of about 185 MBq of 123I-ioﬂupane
SPECT, following a standard protocol described in details elsewhere
(Garibotto et al., 2013). Images were corrected for scatter using a tri-
ple-energy window method and for a uniform attenuation correction.2.3. MR image acquisition
Variable MRI protocols were performed according to clinical routine
procedures that evolved over the 10-year study period. However amin-
imumof a T2, ﬂuid attenuation inversion recovery (FLAIR) and diffusion
weighted imaging (DWI) or diffusion tensor imaging (DTI) were avail-
able in all participants to exclude structural brain lesions. In addition,
the integrity of white matter was analyzed using the Fazekas score
(Fazekas et al., 1987).
103 patients had a high-resolution Magnetization Prepared Rapid
Gradient Echo (MPRAGE) 3DT1brain scan performed on 3.0 Tesla MR
system (Magnetom Trio, Siemens, Erlangen Germany) as part of our
clinical routine protocol (256 × 256 matrix, 176 sections,
1 × 1 × 1 mm3, TE = 2.3 ms, TR = 2300 ms). This subsample was
used to build a 123I-ioﬂupane SPECT template in Montreal Neurological
Institute (MNI) standard space as described earlier (Badoud et al., 2016;
García-Gómez et al., 2013).2.4. Statistical analyses
FSL (FMRIB Software Library version 5.0 http://fsl.fmrib.ox.ac.uk/fsl/
fslwiki), Graphpad Prim (version 6.0, www.graphpad.com), andMatlab
(version R2014a) were used for statistical analyses and classiﬁcation.
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We used a 123I-ioﬂupane SPECT template in Montreal Neurological
Institute (MNI) standard space as described earlier (Badoud et al.,
2016; García-Gómez et al., 2013) in an automatic and operator-inde-
pendent workﬂow. Due to the asymmetrical degeneration of the
nigrostriatal pathways in PD andAPS,we decided to ﬂip all patients pre-
senting predominant clinical symptoms on the left side of the body in
order to obtain a more homogeneous sample with dominant symptom-
atology always at the same hemisphere. Equivalent to previous investi-
gations and existing software packages, intensity was normalized with
respect to the occipital lobe, both for striatal and extra-striatal signals.
2.6. Voxel-wise statistical analysis
The voxel-wise statistical analysis was done using the randomize
function of FSL by permutation testing (n = 5000) and Threshold-Free
Cluster enhancement (TFCE) error multiple comparisons correction at
p b 0.05 considered as signiﬁcant (Smith and Nichols, 2009). Age and
genderwere used as non-explanatory co-regressors to eliminate poten-
tial bias linked to age or gender. Analyses described in this paragraph
were performed inside a striatal mask including the putamen and the
caudate nuclei. The mask was created using the Harvard subcortical
atlas included in FSL.
2.7. Classiﬁcation analysis
We used a combination of simple linear classiﬁers (i.e., linear dis-
criminant analysis) for which each is given a random subset of the fea-
ture space. Putting together suchweak learners in an ensemble leads to
ﬂexible yet robust models (Rokach, 2010). We used the ensemble clas-
siﬁer as implemented in the Matlab Statistics Toolbox (R2014b). The
total number of learners was set to 1500 and the prior probabilities of
the patient labels were assumed uniformly distributed to compensate
for the unequal number of subjects in each category. To reduce the di-
mensionality and exploit spatial correlation - the total number of voxels
was 4916 in the striatum mask and 253,454 in the whole-brain mask
(without striatum, occipital lobe included) - we applied the singular
value decomposition to the data of each patient group (within the
cross-validation fold) and retained 20 and 30 components that
corresponded to 94% and 99% of the explained variance for the striatum
and whole-brain mask, respectively. All training subjects were then
projected onto the principal components of each group, which led to a
total number of features of 80 and 120 for classiﬁcation based on the
striatum and whole-brain mask, respectively. The classiﬁcation accura-
cy was evaluated using leave-one-subject-out cross-validation with
strict separation of training and test data. Based on this classiﬁer, we
performed ROC analysis for the classiﬁcation of PD versus APS and be-
tween the APS classes. The signiﬁcance of the AUC measures was ob-
tained by establishing its null distribution under random
permutations of the patient labels.
3. Results
3.1. Voxel-wise group-level statistical analysis
Group comparisons were performed in two steps. The ﬁrst one
consisted in comparing the differences of dopaminergic uptakes be-
tween PD and APS, while the second one investigated the differences
between APS.
3.2. PD versus APS
The voxel-wise analysis revealed a signiﬁcantly lower 123I-ioﬂupane
uptake in all APS versus PD in the head of caudate nucleus (p b 0.002).
The Cohen's d standardized measure of effect size (Friston, 2012) forthis cluster is 0.55, which indicates a medium effect. The inverse com-
parison showed a cluster located on the ipsilateral putamen with in-
creased 123I-ioﬂupane uptake in APS compared to PD (p b 0.05); the
Cohen's d=−0.43 indicates a small-to-medium effect size.
Concerning the different types of APS, MSA and PSP exhibited a sig-
niﬁcantly lower 123I-ioﬂupane uptake in the headof the caudate nucleus
(p b 0.002) compared to PD. The effect sizes are d=0.31 and d=0.86,
respectively. The inverse comparison led to no signiﬁcant results.
CBD versus PD revealed increased 123I-ioﬂupane uptake in the puta-
men bilaterally. The effect size d=0.99 is large. The inverse comparison
revealed no signiﬁcant differences (Fig. 1).
3.3. APS versus APS
The comparison within the group of APS, i.e. MSA versus PSP versus
CBD revealed signiﬁcantly lower 123I-ioﬂupane uptake in MSA and PSP
compared to CDB in both putamen and the posterior part of the head
of the caudate nucleus, with the head of the caudate nucleus being
more affected in PSP (Fig. 2). The inverse comparison did not yield
any supra-threshold clusters.
The comparison betweenMSA versus PSP revealed no supra-thresh-
old clusters.
3.4. Classiﬁcation analysis
Although sensitivity in the classiﬁcation PD vs APSwas low, the high
speciﬁcity (84% striatum only; 90%whole brain) showed that APS could
be identiﬁed well. All AUC measures (68% striatum only; 69% whole
brain) are signiﬁcant (p b 0.05).
While voxels in the striatummask were informative for the classiﬁ-
cation, the use of thewhole-brainmaskwithout the striatumwas infor-
mative as well. The whole-brain mask with striatum did not improve
accuracies, which indicates that information was redundant inside and
outside the striatummask, but not complementary.
The classiﬁcation was also signiﬁcant for all APS subtypes (MSA vs
CBD AUC0.80, p b 0.05; MSA vs PSP AUC 0.69 p b 0.05; CBD vs PSP
AUC 0.69 p N 0.05). The results for discriminating PD versus APS and be-
tween APS are illustrated in Table 2. The corresponding ROC curves are
illustrated in Fig. 3.
4. Discussion
In this study, wewere able to demonstrate distinct patterns of dopa-
minergic depletion for PD,MSA, PSP and CBDusing 123I-ioﬂupane SPECT
in a sample of 392 consecutive patients. Multivariate pattern recogni-
tion of 123I-ioﬂupane SPECT discriminated PD, PSP and CBD and MSA.
The classiﬁcation accuracies should be interpreted with respect to the
clinical diagnostic accuracy in particular at early stages of the disease
(Hughes et al., 2002; Italian Neurological Society, 2003) and in light of
the classic view that standard analyses of 123I-ioﬂupane SPECT do not
discriminate PD and degenerative APS (Brooks, 2012; Kägi et al., 2010;
Marek et al., 2000; Pirker et al., 2000a).
4.1. PD versus APS
Our results showed that the atypical forms of parkinsonism, notably
MSA, PSP and CBD, seem to affect the 123I-ioﬂupane striatal uptake fol-
lowing a topographically distinct pattern compared to PD. MSA and
PSP have a signiﬁcantly lower 123I-ioﬂupane uptake in the caudate nu-
cleus, whereas, conversely, CBD demonstrated an increased 123I-
oﬂupane uptake indicating less pronounced dopaminergic depletion
in the putamen as compared to PD.
Due to the fact that the various types of APS have distinct patterns of
nigrostriatal degeneration, the direct comparison between PD and all
APS taken together is thus confounded by the differences in the spatial
Fig. 1. Illustrates the comparison between all APS confounded, onlyMSA, only PSP and only CBDversus PD. APS in general andMSAandPSP inparticular, showed a decreased 123I-ioﬂupane
uptake in the head of caudate nucleus bilaterally yet an increased 123I-ioﬂupane uptake in ipsilateral putamen. CBD versus PD had an increased 123I-ioﬂupane uptake in the head of the
caudate nucleus bilaterally. 123I-ioﬂupane uptake maps superimposed on axial T1 weighted MRI in Montreal Neurological Institute (MNI) standard space with the clinically dominant
symptomatic side on the right hemisphere. Threshold-Free Cluster enhancement (TFCE) error multiple comparisons correction at p b 0.05.
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quently potentially confounded by the group size composition.
4.2. Speciﬁc patterns of dopaminergic depletion in APS
The MSA group had signiﬁcantly more pronounced dopaminergic
depletion in the head of caudate nucleus bilaterally as compared to
PD. This result is consistent with a previous [123I]β-CIT SPECT study in
8 MSA versus 11 PD patients, demonstrating a signiﬁcant decrease of
SPECT signal in the head of the caudate nucleus and the anterior part
of the putamen in the MSA group (Nocker et al., 2012). Moreover, and
in linewith the current results, several investigations previously report-
ed a decreased 123I-ioﬂupane uptake in MSA as compared to PD (Pirker
et al., 2000a; Varrone et al., 2001).
However, at variancewith our study, the results presented by Pirker
et al. were obtained by calculating values in manually drawn ROI that
could introduce important variability in the data (Pirker et al., 2000a).
Similarly, Varrone and colleagues did not perform spatial normalization
before setting their ROI template. Thismethod is also at risk of introduc-
ing ameasurement bias (Varrone et al., 2001). Finally, Scherﬂer and col-
leagues chose to conduct voxel-wise analysis using statistical
parametricmapping software (SPM) following the same line as our pro-
tocol (Scherﬂer et al., 2005). Nevertheless, they achieved spatial nor-
malization through an indirect method consisting of transferring theFig. 2.MSA and PSPversus CBDhaddecreased 123I-ioﬂupaneuptake inputamenand head of cau
the comparison between MSA versus PSP revealed no supra-threshold clusters. Illustration equ[123I]β-CIT SPECT images to a 18F-DOPA PET template whereas we de-
cided to create a study speciﬁc functional template for the exact modal-
ity needed (123I-ioﬂupane SPECT).
The asymmetrical pattern of PD versus MSA, showing a more signif-
icant decrease on the contralateral side, can be related to the fact that
the contra/ipsilateral signal asymmetry is likely to bemore pronounced
in PD than in MSA (Varrone et al., 2001).
Concerning PSP, the dopaminergic depletion is also more pro-
nounced in the head of the caudate nucleus as compared to PD. This pat-
tern is similar to the MSA pattern discussed above.
Previous investigations demonstrated that PSP is characterized by a
more uniform reduction of the striatal dopaminergic uptake both in the
caudate nucleus and the putamen and by a low left/right asymmetry
(Antonini et al., 2003; Brooks, 2010). Globally, the dopaminergic
nigrostriatal pathway seems to be more severely affected in PSP than
in PD (Brooks et al., 1990). In agreement with our results, a previous
[123I]β-CIT SPECT study in 14 PSP patients and 17 PD patients demon-
strates a signiﬁcantly lower signal in the caudate nuclei in the PSP
group (Seppi et al., 2006).
With respect to CBD, there is increased 123I-ioﬂupane uptake
representing less dopaminergic depletion in bilateral putamen as com-
pared to PD. These results indicate that CBD affects the dopaminergic
system less severely in the putamen and are consistent with the obser-
vation that the dopaminergic system is less severely affected in CBD asdate nucleus bilaterally. The inverse comparison between CBD versusMSAor PSP aswell as
ivalent to Fig. 1.
Table 2
Classiﬁcation results in terms of sensitivity and speciﬁcity (ﬁrst line) and area-under-
curve (AUC) of the ROC analysis (second line). All the AUC measures are signiﬁcant (p b
0.05).
PD vs APS APS
MSA vs CBD MSA vs PSP CBD vs PSP
Striatum only 45%/84% 75%/86% 50%/71% 69%/65%
0.68, p b 0.05 0.79, p b 0.05 0.67, p b 0.05 0.63, p b 0.05
Extra-striatum 26%/86% 55%/84% 50%/75% 67%/71%
0.68, p b 0.05 0.76, p b 0.05 0.68, p b 0.05 0.69, p b 0.05
Whole-brain 28%/90% 78%/95% 58%/71% 67%/65%
0.69, p b 0.05 0.80, p b 0.05 0.69, p b 0.05 0.68, p b 0.05
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neuropathologically proven CBD cases, 123I-ioﬂupane uptake has even
been found normal (Kaasinen et al., 2013).4.3. MSA versus PSP versus CBD
MSA and PSP exhibit signiﬁcantly stronger dopaminergic depletion
in the head of caudate nucleus and putamen as compared to CBD.
These results are not in line with the study published by Pirker and col-
leagues suggesting no signiﬁcant difference between CBD, PSP andMSA
in terms of dopaminergic denervation (Pirker et al., 2000b). However,Fig. 3.Receiver-operating-characteristics (ROC) curves that show the speciﬁcity/sensitivity trad
PSP (B).the authors conducted an analysis comparing the average striatal activ-
ities and included only four CBD patients.
4.4. Classiﬁcation
The accuracy of PD versus APS is about 68% and the high speciﬁcity
(84–90%) indicates that the classiﬁer is particularly useful for
conﬁrming APS cases. Discriminating between APS cases has highest ac-
curacies for MSA versus CBD, and slightly less for MSA versus PSP and
CBD versus PSP.
Two previous investigations by Palumbo et al. and by Segovia et al.
assessed classiﬁcation performance of PD versus controls (Palumbo et
al., 2014; Segovia et al., 2012). Note that the classiﬁcation accuracies
of 73.9% and 94.7%, respectively, exceed the classiﬁcation accuracy of
the current investigation due to the fact that the discrimination of a dis-
ease condition associated with a clear dopaminergic depletion versus a
healthy control group is much easier than the classiﬁcation of several
disease conditions which signiﬁcantly affect the dopaminergic system.
Even if some subtle differences in 123I-Ioﬂupane uptake between PD
and APS were previously reported, there is a general agreement that
these differences are subtle and consequently the visual inspection of
123I-ioﬂupane uptake maps does not allow for an accurate diagnosis
(Brooks, 2012; Kägi et al., 2010; Marek et al., 2000; Pirker et al.,
2000a). The presented operator-independent classiﬁcation analysis of
the complex pattern of dopaminergic depletion, which providede-off of the classiﬁers for PD versus all APS (A) and in-betweenAPS subtypesMSA, CBD and
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clinical diagnosis of individual patients.
4.5. Striatal versus extra-striatal signal
The 123I-ioﬂupane uptake is most pronounced in the nigrostriatal
system (Booij et al., 1997a, 1997b), and, consequently, most previous
investigations have focused on this brain region. Based on the assump-
tion that PD and APSmight also affect the 123I-Ioﬂupane uptake outside
the striatum, we performed the classiﬁcation analysis three times, once
only within the striatum, once in the remaining brain outside the stria-
tum, and once using the entire brain. As expected, the striatum was
most informative for the classiﬁcation. Nevertheless, above-chance clas-
siﬁcation was possible even when considering only the regions outside
the striatum. This indicates that dopaminergic impairment of extra-
striatal brain regions in PD and APS can be evaluated by advanced anal-
ysis techniques ofmolecular imaging. Yet, some studies have put in light
an afﬁnity of 123I-Ioﬂupane for noradrenergic and serotoninergic recep-
tors, especially within extrastriatal areas (Koch et al., 2014). Thus, non-
dopaminergic uptake has to be taken into account for the interpretation
of our results. Indeed, PD has been shown to be also associated with
non-dopaminergic modiﬁcations (H. Braak and E. Braak, 2000). The
whole-brain analysis did not improve accuracies, which might indicate
that informationwas redundant inside and outside the striatum, but not
complementary. While previous studies suggested that the striatum
was the only region to provide relevant information regarding the
state of the nigrostriatal pathway (Gaig et al., 2006; Seibyl et al.,
2013), our results indicate that extra-striatal regions also convey rele-
vant information. For example, one recent investigation indicates that
extra-striatal 123I-ioﬂupanemodiﬁcation can be observed in the context
of addiction (Leroy et al., 2012). In PD, extra-striatal dopaminergic im-
pairment has been demonstrated, notably in ventral midbrain (Joutsa
et al., 2015). An interesting avenue for future research is to investigate
to what extent the discriminative information relies on textural
features.
4.6. Strengths and limitations
The large cohort used for this study (392 patients) represents its
major asset. Additionally, all patients were scanned consecutively on
the same machine using the same protocol of acquisition. In order to
avoid operator-related variability, all post-processing procedures were
conducted in an operator-independent manner including the creation
of a study speciﬁc template. Sex and age data were used as non-explan-
atory co-regressors in order to compensate for theirwell-known impact
on the nigrostriatal pathway (Nicastro et al., 2016).
The retrospective nature of this study is an important limitation, yet
the clinical follow-up, typically of several years for most patients,
allowed some diagnostic reallocation, whichmay also be seen as an ad-
vantage for the purpose of this diagnosis-oriented study. Moreover, an
impact of anti-parkinsonianmedications on the images cannot be total-
ly excluded even if several studies have not shown signiﬁcant conse-
quences regarding 123I-FP CIT SPECT acquisition (Ahlskog et al., 1999).
Finally, neuropathological data were not available for the vast majority
of patients, so that diagnosis of PD and APS is based on well-established
clinical diagnostic criteria.
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